Finally, the interest in ROR-1 as target is supported by two bi-specific antibodies (ROR1-CD3-DART and APVO425) that aim to redirect cytotoxic T-cells to ROR-expressing cells (182) and by a novel anti-ROR1 single-chain (sc) antibody able to induce apoptotic death of CLL lines and primary CLL cells (186). The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.